

Management of advanced genitourinary tumors

Filippo Pietrantonio, Pamela Biondani, Elena Verzoni, and Giuseppe Procopio

Medical Oncology Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

ABSTRACT

The management of advanced genitourinary tumors is rapidly evolving thanks to the clinical availability of several targeted drugs with different mechanisms of action. Among clinicians, in-depth knowledge of all the aspects of the disease, together with the capacity to interpret and accurately correlate clinical data and imaging findings, are strongly needed. Moreover, the optimization of treatment sequences might lead to better disease control with respect to prognostic categories, radiological monitoring and newer biomarkers. Among the genitourinary tumors, only few data are available on bladder, testicular and penile cancers. Our report is supported by scientific and clinical experience in renal cell carcinoma and prostate cancer.

Key words: renal cell carcinoma, targeted therapies, genitourinary tumors, RECIST, sunitinib, sorafenib.

Report from the First Milan Conference on Urologic Tumors. Milan, 27-28 January 2012.

The authors have no conflicts of interest to declare.

Correspondence to: Giuseppe Procopio, MD, Medical Oncology Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian, 1, 20133 Milan, Italy.
Tel +39-02-23903066;
fax +39-02-23902149;
email giuseppe.procopio@istitutotumori.mi.it